Protalex Inc. (NASDAQ:PRTX) released its quarterly earnings data on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
Protalex (PRTX) remained flat at $0.90 on Thursday. The company has a 50-day moving average price of $0.88 and a 200-day moving average price of $0.81. Protalex has a 12 month low of $0.31 and a 12 month high of $3.00. The stock’s market capitalization is $25.89 million.
COPYRIGHT VIOLATION WARNING: “Protalex Inc. (PRTX) Releases Earnings Results” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/12/protalex-inc-prtx-releases-earnings-results.html.
Protalex, Inc is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company’s lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system.
What are top analysts saying about Protalex Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Protalex Inc. and related companies.